Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment option ..read more

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erika Hamilton, MD The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations or chemotherapy-based regimens. And now, the preliminary results are here. Joining Dr. Charles Turck to share what we’ve learned so far from the ELECTRA trial is study investigator Dr. Erika Hamilton ..read more

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mary Frances McMullin, MD The MOMENTUM study evaluated the impact of the treatment option momelotinib on patient-reported outcomes, including symptom burden and overall quality of life. Joining Dr. Charles Turck to share the key findings and potential implications for myelofibrosis care is Dr. Mary Francis McMullin, who co-authored and presented the poster at the American Society of Hematology (ASH) Annual Meeting and Exposition ..read more

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Douglas Tremblay, MD Based on three randomized-controlled trials, the JAK inhibitor momelotinib has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly in patients with myelofibrosis. But what do we know about its long-term safety? That’s what a recent study explored, and now, Dr. Douglas Trembley is here to share the findings from the largest clinical trial safety database for a JAK inhibitor in myelofibrosis. Dr. Trembley is an Assistant Professor at the Icahn School of Medicine at Mount Sinai in New York ..read more

Host: Gates B. Colbert, MD Guest: Ryan Cassaday, MD According to the available long-term data, CAR T-cell therapy boosts overall survival and durable remission rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Given this data, it’s important to know how we can best identify appropriate patients for this approach and manage adverse events so they can achieve those long-term benefits. To learn more about the available data and key considerations for using CAR T-cell therapy to treat relapsed/refractory B-ALL, Dr. Gates Colbert speaks with Dr. Ryan Cassaday ..read more

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tara Graff, DO, MS When it comes to managing patients with high-risk mantle cell lymphoma, several factors impact their candidacy for CAR T-cell therapy, including time to relapse, TP53 mutation status, age, and even social considerations. Joining Dr. Charles Turck to discuss how we can use these factors to identify patients with high-risk mantle cell lymphoma who would most likely benefit from CAR T-cell therapy is medical oncologist Dr. Tara Graff ..read more

Host: Matt Birnholz, MD The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive management strategy by addressing the underlying molecular mechanism of anemia. Learn more about the trial design and results with Dr. Matt Birnholz ..read more

Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O’Donnell, Director of Early Detection and Prevention at Dana-Farber ..read more

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua E. Reuss, MD The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center ..read more

Guest: Elizabeth Montgomery, MD Guest: John L. Marshall, MD This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Fin ..read more